REGULATORY
Intractable Neurological, Psychiatric Diseases Initially Eyed for PMDA-NCNP Drug Development Guidelines
A collaboration pact inked by the National Center of Neurology and Psychiatry (NCNP) and the Pharmaceuticals and Medical Devices Agency (PMDA) earlier this month will explore ways to speed up drug development in the areas of neurology and psychiatry, initially…
To read the full story
Related Article
- PMDA Inks Comprehensive Collaboration Accord with NCNP
July 12, 2016
REGULATORY
- Pharma Urges Pricing Rewards to Bolster Japan’s Drug Discovery Strength
September 24, 2026
- New Digital Minister Furukawa Pledges Push for Healthy Longevity
September 24, 2026
- MHLW Eyes Higher Long-Term Care Premiums for Wealthier Seniors
September 24, 2026
- Nippon Ishin’s Urano Named Senior Vice Health Minister in Takaichi Cabinet
September 24, 2026
- Ueno Vows to Advance Drug Innovation, Advanced Medicine in 2nd Term
September 24, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





